Skip to main content


Generic name: crizanlizumab-tmca
Dosage form: Injection, for intravenous use
Drug class: Miscellaneous uncategorized agents
Approval date: November 15, 2019
Company: Novartis Pharmaceuticals Corporation

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 26, 2022.

Treatment for: Pain Crises in Sickle Cell Disease

Patient Information

Read this Patient Information before you start treatment. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is Adakveo?

Adakveo is used:

It is not known if Adakveo is safe and effective in children under 16 years of age.


Adakveo may cause serious side effects, including:
Infusion reactions. Infusion reactions may happen within 24 hours of receiving an infusion of Adakveo. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infusion reaction:

Your healthcare provider may monitor you for signs and symptoms of infusion reactions.

Adakveo may interfere with a certain blood test.

Tell your healthcare providers that you are receiving Adakveo before having any blood tests. Adakveo may interfere with a laboratory test to measure your platelet counts.

See Adakveo side effects for more information about side effects.

Before receiving Adakveo

Before you receive Adakveo, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all of the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

How will I receive Adakveo?

Adakveo side effects

Adakveo may cause serious side effects. See Important information.

The most common side effects include:

These are not all of the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Adakveo.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for more information.

What are the ingredients in Adakveo?

Active ingredient: crizanlizumab-tmca
Inactive ingredients: citric acid, polysorbate 80, sodium citrate, and water for injection

Popular FAQ

Adakveo injection is a targeted biologic P-selectin inhibitor that blocks interactions between certain blood cells and blood vessels to make them less “sticky”. This helps to reduce how often painful crises occur in patients with sickle cell disease. Continue reading

Adakveo is administered by an intravenous (IV) infusion over 30 minutes. The correct dose of Adakveo for you will be mixed in a sterile IV bag containing 0.9% Sodium Chloride for injection or 5% Dextrose for injection and given directly into your vein via a small, hollow, plastic tube called a cannula. Adakveo cannot be self-administered at home, it must be prepared and administered by a health professional. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.